Contact: Alexander Shtifman
Phone: 617-713-8989
alex...@childrens.harvard.edu

Liron David, Ph.D., and Leng-Siew Yeap, Ph.D., research fellows in the Program in Cellular and Molecular Medicine at Boston Children's Hospital have been named recipients of grants from the Cancer Research Institute-Irvington Institute Fellowship Program to further their research in the field of cancer immunology.

  • Dr. David's project titled ‘Molecular elucidation of the CBM complex in NF-kappaB activation by antigen receptors' is being conducted in the laboratory of Hao Wu, Ph.D.
  • Dr. Yeap's project titled ‘Mechanisms by which DNA sequence influence AID targeting in antibody diversity and B lymphocyte cancer' is being conducted in the laboratory of Frederick W. Alt, Ph.D.

Cancer Research Institute, Inc. (CRI), the oldest and largest nonprofit funder of global research efforts to discover and develop immunotherapies to prevent, treat, and eventually cure all cancers, announced today that it has committed more than $10 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development at research centers worldwide.

"As the only nonprofit funder dedicated exclusively to furthering the science and clinical application of cancer immunology, Cancer Research Institute is excited and proud to support such highly promising studies and investigators," says James P. Allison, Ph.D., director of the CRI Scientific Advisory Council.

Supported research will focus on some of the most critical questions and innovative approaches in cancer immunology and immunotherapy, including:

  • targeting immunosuppression in the tumor microenvironment to improve outcomes for difficult-to-treat cancers, such as pancreatic cancer
  • developing and optimizing novel immunotherapy techniques, including bispecific antibodies for the treatment of brain cancer and genetically engineered T cell therapy for leukemia and lymphoma
  • combining targeted therapy with immune checkpoint blockade to improve treatment for melanoma
  • using genomics-based approaches to predict patient responses to anti-CTLA-4 checkpoint blockade immunotherapy and develop personalized vaccines for cancer patients
  • reengineering antibodies to enhance T cell activation to eradicate tumors

For a list of all awards and project descriptions, visit http://cancerresearch.org/programs/2012/.

About the Cancer Research Institute

The Cancer Research Institute (CRI), established in 1953, is the world's only nonprofit organization dedicated exclusively to transforming cancer patient care by advancing scientific efforts to develop new and effective immune system-based strategies to prevent, diagnose, treat, and eventually cure all cancers. Guided by a world-renowned Scientific Advisory Council that includes three Nobel laureates and 30 members of the National Academy of Sciences, CRI has invested more than $225 million in support of research conducted by immunologists and tumor immunologists at the world's leading medical centers and universities, and has contributed to many of the key scientific advances that demonstrate the potential for immunotherapy to change the face of cancer treatment.

To accelerate the pace of progress in the field, CRI convenes and coordinates global collaborations among academics, industry scientists and decision makers, regulatory representatives, and health research associations focused on discovery, development, and refinement of new cancer immunotherapies. A founding visionary and scientific leader in tumor immunology, CRI is helping to shape the emerging field of immuno-oncology, and is ushering in a new era of medical progress to bring more treatment options to cancer patients sooner.